Newsletter

Healthcare Stocks

ASX Healthcare Sector Sheds 6% in a Day: 3 Stocks Now Trading at Bargain Levels

The ASX healthcare sector lost 6% in a single day on Wednesday, its worst session in years. The trigger was Cochlear (ASX:COH), which fell 40.7% to a decade-low of A$99.58 after slashing its profit guidance. The damage spread well beyond Cochlear itself, with CSL (ASX:CSL) down 5.7%, ResMed (ASX:RMD) off 2.5%, and most other healthcare…

ByUjjwal MaheshwariApril 23, 2026

Shares In Cochlear (ASX:COH) Plunge Over 35% As FY26 Guidance Is Slashed By Nearly A Third! Is It A Buy The Dip Opportunity?

If you own shares in Cochlear (ASX:COH), you had a pretty bad morning. The company delivered one of the most significant earnings guidance downgrades in its listed history this morning, cutting its FY26 underlying net profit guidance to A$290–330m from a previously disclosed range of A$435–460m. The revision (a reduction of roughly 30% at the…

ByNick SundichApril 22, 2026

Dimerix And Its DMX-200 (Qytovra) Therapy Approach Their Most Important Catalyst

After several years of advancing DMX-200/Qytovra, Dimerix is entering the most consequential chapter of its life. The upcoming blinded statistical powering analysis for ACTION3 is the moment where all of that groundwork will likely pay off. Dimerix has been advancing DMX-200/Qytovra for several years DMX-200 is a targeted anti‑inflammatory therapy designed to block the CCR2 pathway…

ByNick SundichApril 21, 2026

How To Read a Balance Sheet As An Investor: The 7 Questions Prudent Investors Need to Ask!

Knowing how to read a balance sheet is a key skill investors need to know, because the balance sheet is the most underrated document in an annual report. Most new investors skip straight to earnings - perhaps not knowing how importance the balance sheet is or having an appreciate but not knowing how to read…

ByNick SundichApril 21, 2026

Monash IVF (ASX:MVF) Rejects A$0.90 Soul Patts Bid: Shares Slide 6% on Second Knockback

Monash IVF Knockback Sends Shares Lower Monash IVF Group (ASX:MVF) shares slid nearly 6% to A$0.72 on Monday after the board rejected a revised A$0.90 per share takeover bid from a consortium led by Genesis Capital and Washington H. Soul Pattinson (ASX:SOL). This is the second rejection in five months, following the knockback of an…

ByUjjwal MaheshwariApril 21, 2026

Immutep (ASX:IMM) wins FDA orphan status as efti Phase 2 hits 51.5% endpoint

Rebound gains fuel as FDA orphan tag backs 38-patient efti data Immutep (ASX:IMM) has received FDA orphan drug designation for eftilagimod alfa, or efti, in soft tissue sarcoma. This is not approval to sell the drug yet, but it is still a meaningful regulatory step because it recognises soft tissue sarcoma as a rare cancer…

ByCharlie YouldenApril 15, 2026

Sick Charts: Why The ASX’s 3 Pathology Stocks Are All Under the Weather

The ASX's 3 pathology stocks: Sonic Healthcare (ASX:SHL), Healius (ASX:HLS) and Australian Clinical Labs (ASX:ACL); have delivered a torrid experience for shareholders over the past two to three years. Sonic, the global heavyweight, has fallen nearly 20% since early 2025 and recently traded at decade lows. Healius, long the sector’s problem child, has lost more than…

ByNick SundichApril 15, 2026

Pro Medicus (ASX:PME) Banks A$80M in One Month: Is the 60% Selloff Finally a Buy?

Pro Medicus Secures A$80M Amid 60% Selloff Pro Medicus (ASX:PME) jumped 4.3% on Monday after securing a A$37 million contract renewal with Northwestern Medicine at higher per-exam fees than its original deal. That single win pushed total contract announcements to nearly A$80 million in just one month. Yet the stock still trades around A$132, down…

ByUjjwal MaheshwariApril 15, 2026

Telix Pharmaceuticals (ASX:TLX) Regeneron $14b revenue partner, 49m shorts face pressure

$40m Regeneron cheque validates RLS as 49m shorts watch Telix Pharmaceuticals (ASX:TLX) is building momentum after the positive NDA update for Pixclara, its PET imaging agent for glioma, a form of brain cancer. Today, the company added to that momentum by announcing a 50/50 partnership with Regeneron to develop and commercialise a new generation of…

ByCharlie YouldenApril 13, 2026

Here Are 4 Stock Market Sectors With High Margins, And 4 With Low Margins!

Many investors may prefer stock market sectors with high margins over those with low margins. Profit margins are one of the simplest signals investors reach for when assessing business quality, yet they are also one of the most frequently misread. It is tempting to treat margins as a scoreboard and just say high is good and…

ByNick SundichApril 13, 2026

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

ASX Healthcare Sector Sheds 6% in a Day: 3 Stocks Now Trading at Bargain Levels

Shares In Cochlear (ASX:COH) Plunge Over 35% As FY26 Guidance Is Slashed By Nearly A Third! Is It A Buy The Dip Opportunity?

Dimerix And Its DMX-200 (Qytovra) Therapy Approach Their Most Important Catalyst

How To Read a Balance Sheet As An Investor: The 7 Questions Prudent Investors Need to Ask!

Monash IVF (ASX:MVF) Rejects A$0.90 Soul Patts Bid: Shares Slide 6% on Second Knockback

Immutep (ASX:IMM) wins FDA orphan status as efti Phase 2 hits 51.5% endpoint

Sick Charts: Why The ASX’s 3 Pathology Stocks Are All Under the Weather

Pro Medicus (ASX:PME) Banks A$80M in One Month: Is the 60% Selloff Finally a Buy?

Telix Pharmaceuticals (ASX:TLX) Regeneron $14b revenue partner, 49m shorts face pressure

Here Are 4 Stock Market Sectors With High Margins, And 4 With Low Margins!

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here